We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




Blocking Nitric Oxide Formation May Increase Effectiveness of Antibiotics

By LabMedica International staff writers
Posted on 30 Sep 2009
Nitric oxide (NO) generated by nitric oxide synthases (NOS) in some Gram-positive bacteria increases the resistance of the bacteria to a broad spectrum of antibiotics, so drugs that inhibit NOS activity may increase the effectiveness of antimicrobial therapy.

Nitric oxide is a crucial physiologic messenger molecule that is thought to play a role in blood pressure regulation, control of blood clotting, immune defense, digestion, the senses of sight and smell, and possibly learning and memory. More...
Nitric oxide may also participate in disease processes such as diabetes, stroke, hypertension, impotence, septic shock, and long-term depression. Nitric oxide can freely diffuse through aqueous solutions or membranes, reacting rapidly with metal centers in cellular proteins and with reactive groups in other cellular molecules.

Investigators from the New York University School of Medicine (New York, USA) earlier had shown that bacteria mobilize NO to defend against oxidative stress. In the current study, which was published in September 11, 2009, issue of the journal Science, the authors demonstrated that many antibiotics cause oxidative stress in bacteria, often resulting in their death, and that NO opposes this effect.

In addition to alleviating oxidative stress NO provided further protection to the bacteria by chemically modifying toxic compounds. The authors therefore suggested that commercially available inhibitors of NOS could render antibiotic resistant bacteria such as methicillin-resistant Staphylococcus aureus (MRSA) and anthrax more sensitive to available drugs.

"Developing new medications to fight antibiotic resistant bacteria like MRSA is a huge hurdle, associated with great cost and countless safety issues," said senior author Dr. Evgeny A. Nudler, a professor of biochemistry at the New York University School of Medicine. "Here, we have a short cut, where we do not have to invent new antibiotics. Instead, we can enhance the activity of well established ones, making them more effective at lower doses."

Related Links:
New York University School of Medicine


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Neonatal Heel Incision Device
Tenderfoot
Creatinine/eGFR Meter
StatSensor® Creatinine/eGFR Meter
Chromogenic Culture System
InTray™ COLOREX™ ECC
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Researchers developed three mathematical biomarkers from routine PSA blood tests that may help predict early prostate cancer treatment outcomes and personalize adaptive therapy (Image Credit: Adobe Stock)

Mathematical Biomarkers Use Routine Blood Tests to Guide Adaptive Prostate Cancer Therapy

Personalizing systemic therapy for prostate cancer remains challenging because tumors can evolve under treatment pressure, driving resistance and early relapse. Continuous high-dose regimens may initially... Read more

Molecular Diagnostics

view channel
Image: The duet mosaic family comprises duet +modC mosaic and duet 6-base mosaic, two cfDNA-optimized multiomic sequencing workflows for liquid biopsy and translational research. (Photo courtesy of bimodal)

New Liquid Biopsy Workflow Maximizes Tumor Signals from Limited Blood Samples

Liquid biopsy seeks to detect tumor-derived signals from small blood samples, but circulating cell-free DNA is scarce and heterogeneous, limiting sensitivity. Combining complementary signals such as methylation,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.